Table 1.
Number of individuals (n = 88) | ||||
---|---|---|---|---|
Study | Dose | PK | Receptor occupancy | Viral load |
Healthy Volunteers (n = 63) | Placebo | – | 8 | – |
3 mg b.i.d. | 5 | 5 | – | |
10 mg b.i.d. | 5 | 5 | – | |
25 mg b.i.d. | 9 | 9 | – | |
100 mg b.i.d. | 9 | 9 | – | |
300 mg b.i.d. | 9 | – | – | |
600 mg q.d. | 18 | – | – | |
Total | 55 | 36 | ||
Patients (n = 25) | Placebo | – | 8 | 8 |
25 mg q.d. | 9* | 8 | 8 | |
100 mg b.i.d. | 8 | 8 | 7† | |
Total | 17 | 24 | 23 |
One patient had PK measurements only on day 1 and no receptor occupancy measurements.
One patient was excluded from viral load analysis because he did not meet the inclusion criteria.